Skip to main content
. 2021 Mar 31;20(1):939–950. doi: 10.1007/s40200-021-00779-2

Table 2.

Overall and subgroup wise prevalence of diabetes mellitus in hospitalized COVID-19 patients

Subgroup Category Number of Studies Number of admitted COVID-19 patients Number of DM patients Mean prevalence of DM 95 % prediction interval Heterogeneity measures
% 95 % CI I2 (%) Q (p-value)
Continent Asia 14 9,175 944 17.0 11.0–24.0 0.0–48.0 98.13 < 0.01
Europe 3 20,775 5105 26.0 18.0–34.0 - - -
North America 4 14,508 4445 26.0 17.0–35.0 0.0–75.0 99.31 < 0.01
Country China 9 5,919 767 18.0 10.0–26.0 0.0–54.0 98.26 < 0.01
India 1 21 2 10.0 1.0–30.00 Inestimable - -
Iran 1 2,964 113 4.0 3.0–5.0 Inestimable - -
Italy 1 410 69 17.0 13.0–21.0 Inestimable - -
Korea 2 208 42* 20.0 15.0–25.0 Inestimable - -
Oman 1 63 20 32.0 21.0–45.0 Inestimable - -
UK 2 20,365 5036 25.0 24.0–25.0 Inestimable - -
US 4 14,508 4445 26.0 17.0–35.0 0.0–75.0 99.31 < 0.01
COVID-19 diagnosis RT-PCR 17 20,758 5315 21.0 15.0–28.0 1.0–55.0 99.13 < 0.01
Multiple modes 4 23,700 5179 16.0 4.0–34.0 0.0–98.0 99.72 < 0.01
DM diagnosis Method specified 4 1,918 391 28.0 9.0–53.0 0.0–100 99.02 < 0.01
Unclear 17 42,540 10,103 18.0 13.0–24.0 1.0–48.0 99.40 < 0.01
DM types Mixed T1DM patients and T2DM 2 642 156 24.0 20.0–27.0 Inestimable - -
Type 2 3 5,922 1863 29.0 23.0–34.0 Inestimable - -
Unclear 16 37,894 8475 18.0 12.0–25.0 0.0–51.0 99.44 < 0.01
COVID-19 severity Critically ill 3 282 64 22.0 16.0–28.0 Inestimable - -
Not Critically ill 3 2,129 161 8.0 2.0–18.0 Inestimable - -
Unclear 15 42,047 10,269 22.0 17.0–29.0 3.0–53.0 99.42 < 0.01
Sample size < 100 12 3,608 462 18.0 11.0–27.0 0.0–56.0 96.80 < 0.01
 100 9 40,850 10,032 22.0 15.0–30.0 2.0–55.0 99.65 < 0.01
Overall NA 21 44,458 10,494 20.0 15.0–25.0 0.02–0.50 99.33 < 0.01

*only diabetes patients for whom mortality data was available were included